Stereotaxis (STXS) said it has received FDA 510(k) clearance for the Synchrony system. Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony's 55 4K ultra-high-definition display consolidates the viewing and control of all disparate systems in the lab. It is made available with SynX, a cloud-based HIPAA and GDPR-compliant app that allows for secure remote connectivity, collaboration, recording, and monitoring of the cath lab.
Stereotaxis reiterated its guidance of over $3 million in revenue in the current year from Synchrony systems placed independent of robotic systems.
In pre-market trading on NYSE American, Stereotaxis shares are up 5.8 percent to $2.0.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.